Gary Schiller, MD, UCLA Medical Center

home / authors / gary-schiller-md-ucla-medical-center

Articles

Treatment Approach Amid COVID-19 Pandemic

Treatment Approach Amid COVID-19 Pandemic

Gary Schiller, MD, UCLA Medical Center;Salman Fazal, MD, West Penn Hospital
August 20th 2020

Read More

Novel Agents for BPDCN Management

Novel Agents for BPDCN Management

Gary Schiller, MD, UCLA Medical Center;Salman Fazal, MD, West Penn Hospital
August 20th 2020

Read More

Second-Line Treatment Options

Second-Line Treatment Options

Gary Schiller, MD, UCLA Medical Center;Salman Fazal, MD, West Penn Hospital
August 20th 2020

Read More

Standard of Care for BPDCN Treatment

Standard of Care for BPDCN Treatment

Gary Schiller, MD, UCLA Medical Center;Salman Fazal, MD, West Penn Hospital
August 20th 2020

Read More

BPDCN Prevalence, Patient Profile, and Work-Up

BPDCN Prevalence, Patient Profile, and Work-Up

Gary Schiller, MD, UCLA Medical Center;Salman Fazal, MD, West Penn Hospital
August 20th 2020

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data